Alzamend Neuro regains Nasdaq listing compliance after meeting stockholders’ equity rule
ALZN•Nasdaq compliance restored after equity threshold met
- Alzamend Neuro regained compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity, closing a continued-listing deficiency matter.
- Nasdaq’s Sept. 14 notice cited $5.8 million of stockholders’ equity in the Form 10-Q for the quarter ended July 31, 2026.
- The company had faced a Nasdaq deficiency notice on March 20, 2026, then received an extension to Sept. 16, 2026 to cure it.
